Abstract:
An assay method for determining presence of a target antibody or antigen in a specimen qualitatively or quantitatively by mixing the specimen with an antigen or antibody immunologically reactive with the target antibody or antigen, and assaying the level of the immunological agglutination reaction, wherein the reactive antigen or antibody is effectively immobilized on the carrier via an amino acid sequence capable of binding to the carrier.

Description:
BACKGROUND OF THE INVENTION  
         [0001]    1. Field of the Invention  
           [0002]    The present invention relates to an immunoassay process of a target antibody or antigen in a specimen, which comprises mixing the specimen with an antigen or antibody corresponding to the target antibody or antigen to elicit immuno-agglutination reaction, and then detecting or determining the agglutination state. The present invention also relates to a reagent used in the assay and a method for producing the reagent.  
           [0003]    2. Related Background Art  
           [0004]    In clinical laboratory tests, various components in biological samples such as blood or urine are assayed to diagnose various diseases, for which various assay methods have been developed and used. For example, enzymatic assays using enzyme reaction and immunoassays using antigen-antibody reaction have widely been used. In recent years, especially, immunoassay utilizing highly specific antigen-antibody reactions has been used more frequently because of its high accuracy.  
           [0005]    In the field of environmental and food analysis, usually the target substances are extracted from the sample, concentrated and then analyzed by high performance liquid chromatography or gas chromatography. However, in recent years, as seen with problems of dioxin or endocrine disrupting chemicals (so-called environmental hormones), assay of substances of extremely low concentrations, assay of a wide variety of target species, rapid assay of a large number of specimens, etc. are required more and more, which conventional methods have difficulty to cope with. Thus, also in the field of environmental and food analysis, immunoassay using antigen-antibody reaction is beginning to be used.  
           [0006]    Examples of immunoassay include immunoagglutination assay (immunonephelometry and latex agglutination assay), enzyme immunoassay, and radioimmunoassay, which may be selected to suit the purposes. Immunoagglutination assay, especially, are widely used as a simple on-site assay method, because it not necessarily requires large expensive assay apparatuses, and is capable of an easy determination by visual observation. In immunoagglutination assay, an antigen or an antibody is immobilized on a water-insoluble carrier, and the carrier is mixed with a specimen to elicit immune agglutination reaction, and the level of agglutination is determined. Generally, polystyrene latex or gelatin particles are used as the water-insoluble carrier particles (Japanese Patent Application Laid-Open Nos. 11-295313 and 2000-338108). Since these materials are white or transparent, so that special techniques and trainings are required to carry out visual determination.  
           [0007]    In order to solve the above problem, use of a colored insoluble carrier such as a pigment or dye has been proposed for easy visual determination. Japanese Patent Application Laid-Open No. 4-274762 discloses an immunoagglutination assay that uses phthalocyanine pigment as an insoluble carrier to which antibody is immobilized by physical adsorption. As a result, the agglutinate formed by the immune agglutination reaction has a blue color, enabling easy visual determination of the reaction.  
           [0008]    However, when an antigen or antibody is immobilized on an insoluble carrier such as pigment by physical adsorption, sufficient adsorption may not be attained at times, causing problems regarding the production efficiency and storage stability of the assay reagent. Moreover, when an antigen or antibody is immobilized by physical adsorption, due to the difference of hydrophobicity of antigen or antibody, constant and quantitative immobilization of antigen or antibody is often difficult. This seriously affects performance of the assay system, and causes difference between production lots.  
           [0009]    To solve this problem, a method has been proposed in which an antibody is partially denatured to increase its hydrophobicity before the antibody is adsorbed onto an insoluble carrier (Seikagaku Jikken Ho 11 (Biochemical Experiment Method 11), Enzyme Immunoassay, Tokyo Kagaku Dojin Co., Ltd., p. 270, 1989). However, this method has a problem that the antibody may lose its activity by denaturation so that this method can be applied not to all types of antibody.  
         SUMMARY OF THE INVENTION  
         [0010]    Thus, it is an object of the present invention to provide an improved immunoassay method to determine a target antibody or antigen in a specimen qualitatively or quantitatively. It is also an object of the present invention to provide a reagent used in the above assay and a method of producing the reagent.  
           [0011]    The present inventors have found that peptides of certain amino acid sequences can bind to a carrier such as pigment by using screening a peptide library, and that when such peptides are fused to an antigen or an antibody by genetic engineering, the antigen or antibody can efficiently be immobilized on the surface of the carrier, thereby completed the present invention.  
           [0012]    Thus, according to one aspect of the present invention, there is provided an assay method for determining a presence or an amount of a target antibody or antigen in a specimen comprising the steps of:  
           [0013]    preparing a carrier on which an antigen or antibody corresponding to an antibody or antigen in said specimen respectively is immobilized;  
           [0014]    mixing said carrier with said specimen; and  
           [0015]    assaying the level of an immunological agglutination reaction caused by said mixing step,  
           [0016]    wherein said antigen or antibody immobilized on said carrier is bound to said carrier via an amino acid sequence capable of binding to said carrier.  
           [0017]    According to another aspect of the present invention, there is provided an assay reagent for assaying the presence or amount of a target antibody or antigen in a specimen,  
           [0018]    wherein an antigen or antibody corresponding to said antibody or antigen is immobilized on a carrier, and said antigen or antibody immobilized on said carrier is bound to said carrier via an amino acid sequence capable of binding to said carrier.  
           [0019]    According to a further aspect of the present invention, there is provided a method of producing an assay reagent for assaying the presence or amount of a target antibody or antigen in a specimen,  
           [0020]    which comprises a step of immobilizing an antigen or antibody corresponding to said antibody or antigen on a carrier,  
           [0021]    wherein the antigen or antibody immobilized on said carrier is bound to said carrier via an amino acid sequence capable of binding to said carrier.  
           [0022]    Herein, the term “to determine the presence or amount of an antibody or antigen” is used to assay the agglutinated state, that is, including both qualitative determination of the presence or absence of agglutination and quantitative determination of the agglutination level.  
           [0023]    According to the present invention, an antigen or antibody can efficiently be immobilized on the surface of a carrier, and therefore the production process is extremely efficient.  
           [0024]    Moreover, when a color material such as a pigment is used as a carrier, an assay reagent comprising an antigen or antibody immobilized on the surface of the color material has a certain color, so that it can be used as an assay reagent for clinical laboratory tests or environmental or food analysis, with easy visual determination and high reliability.  
         DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT  
         [0025]    A carrier used in the present invention is not particularly limited, and any known carrier for an antigen or antibody used in the conventional antigen-antibody reaction can be used. Examples of such a carrier include organic polymer substances such as organic polymer latex obtained by emulsion polymerization of polystyrene, styrene-butadiene copolymer, styrene-methacrylic acid copolymer, polyglycidyl methacrylate, acrolein-ethylene glycol dimethacrylate copolymer, etc.; inorganic oxides such as silica, silica-alumina and alumina. Pigment can be also used as a carrier. Pigment usable as a carrier is not particularly limited. Examples of such pigment include black pigments such as carbon black, copper oxide, manganese dioxide, aniline black, activated carbon, nonmagnetic ferrite, and magnetite; yellow pigments such as chrome yellow, zinc yellow, yellow iron oxide, cadmium yellow, mineral fast yellow, nickel titanium yellow, Naples yellow, naphthol yellow S, hansa yellow G, hansa yellow 10G, benzidine yellow G, benzidine yellow GR, quinoline yellow lake, permanent yellow NCG, and tartrazine lake; orange pigments such as red chrome yellow, molybdenum orange, permanent orange GTR, pyrazolone orange, Vulcan orange, benzidine orange G, indanthrene brilliant orange RK, and indanthrene brilliant orange GK; red pigments such as iron oxide red, cadmium red lead, mercuric sulfide, cadmium, permanent red 4R, lithol red, pyrazolone red, watching red, calcium salt, lake red C, lake red D, brilliant carmine 6B, brilliant carmine 3B, eosin lake, rhodamine lake B, and alizarin lake; blue pigments such as iron blue, cobalt blue, alkali blue lake, Victoria blue lake, phthalocyanine blue, nonmetallic phthalocyanine blue, partially chlorinated phthalocyanine blues, fast sky blue, and indanthrene blue BC; violet pigments such as manganese violet, fast violet B, and methyl violet lake; green pigments such as chromium oxide, chrome green, pigment green B, malachite green lake, and final yellow green G; white pigments such as flowers of zinc, titanium oxide, antimony white, and zinc sulfide; extenders such as barite powder, barium carbonate, clay, silica, white carbon, talc, and alumina white; and other pigments. However, available pigments are not limited thereto.  
           [0026]    In addition, the above described organic polymeric substance colored with a pigment or dye can be used as a carrier. In such a case, it is preferable to encapsulate the colorant in the polymer so that the colorant would not diffuse from the carrier.  
           [0027]    The shape of the carrier can be selected appropriately depending on the purpose. For example, when an assay target is an antigen and the corresponding antibody is immobilized on the surface of a carrier, particles of 1 nm to 10 μm in diameter may be preferably used, more preferably, particles of 50 nm to 1 μm may be used.  
           [0028]    In the present invention, the antigen or antibody corresponding to a target antibody or antigen (counter antigen or antibody) is not particularly limited. It may be a protein or peptide derived from an organism, a partially modified protein or peptide thereof, an artificially designed protein or peptide, or a fragment thereof, so long as it can cause an antigen-antibody reaction with the target antibody/antigen. For example, when a target is an antigen and the corresponding antibody is immobilized on the surface of a carrier, either a monoclonal antibody or polyclonal antibodies can be used. Alternatively, when a target is an antibody and the corresponding antigen is immobilized on the surface of a carrier, either a protein or peptide can be used as the above antigen.  
           [0029]    For example, when presence of antibodies to Hepatitis C virus (HCV antibodies) in the blood is assayed to diagnose Hepatitis C virus (HCV) infection, known antigenic proteins of the Hepatitis C virus that can elicit antigen-antibody reaction with HCV antibodies can be used as the antigen. For example, one can use at least one selected from the group consisting of structure proteins such as HCV core proteins or envelope proteins, nonstructural proteins such as NS1 protein, NS2 protein, NS3 protein, NS4 protein and NS5 protein, and fragments thereof (Proc. Natl. Acad. Sci. USA, 89, 10011-10015, 1992). Alternatively, modified antigens having addition, deletion, substitution and/or insertion in the amino acid sequence of the above described antigen protein can also be used, as long as it has antigenicity sufficient to carry out the method of the present invention.  
           [0030]    In order to obtain a peptide of an amino acid sequence capable of binding to the carrier (carrier-binding amino acid sequence) of the present invention, for example, the following phage display peptide library method can be used. A phage random peptide library may be constructed, for example, by ligating a synthetic gene of random sequence to a gene encoding a surface protein (e.g., gene III protein) of M13 phage to display the gene product fused to the N-terminus of the surface protein (Scott J K and Smith G P, Science, 249, 386, 1990, Cwirla S E et al., Proc. Natl. Acad. Sci. USA, 87, 6378, 1990). The size of the synthetic gene to be inserted is not particularly limited, as long as it enables stable peptide expression. However, in order that the prepared library may contain all of random sequences and displayed peptides may have binding ability, the gene length encoding 6 to 40 amino acids (which corresponds to a molecular weight of approximately 600 to 4,000) is suitable, more preferably 7 to 18 amino acids.  
           [0031]    To select phages binding to a carrier of interest, the carrier is immobilized in a column or on a plate and contacted with the above library, and then non-binding phages are washed away by washing the column or plate while binding phages are retained. After washing, the retained phages are eluted with acid or the like, and they are then neutralized with a buffer. The neutralized phages are infected to  Escherichia coli  for amplification. This selection is repeated several times, so that clones capable of binding to a carrier of interest are condensed. To isolate a single clone,  E. coli  infected with these phages are grown on a culture plate to form single colonies. Each single colony is cultured in a liquid medium, and thereafter, phages existing in the supernatant of the medium are purified by precipitation with polyethylene glycol or the like. Analysis of the nucleotide sequence reveals the sequence of a binding peptide of interest. To prepare a peptide library having random amino acid sequences, not only the above phage method, but also a method of chemically synthesized peptides can be used. For example, beads method (Lam, K. S. et al., Nature, 354, 82, 1991), liquid phase focusing method (Houghton, R. A. et al., Nature, 354, 84, 1991), microplate method (Fodor, S. P. A. et al., Science, 251, 767, 1991), and other methods have been reported, and any of these methods can be applied in the present invention.  
           [0032]    When two or more types of carrier-binding amino acid sequence are obtained by screening a phage display peptide library, all or part of these sequences may be ligated in suitable combination to use as a carrier-binding amino acid sequence. In this case, it is desired to place a suitable spacer sequence between two amino acid sequences. A preferred spacer sequence consists of three to approximately 400 amino acids. Further, such a spacer sequence may include any amino acid. Most importantly, spacers would not interfere the interaction between the assay target and an antigen or antibody, and not prevent binding of the antigen or antibody to the carrier.  
           [0033]    Carrier-binding amino acid sequences of the present invention can be obtained not only by screening of a random peptide library but also by reasonably designing the sequence on the basis of the chemical properties of the carrier.  
           [0034]    Such a carrier-binding amino acid sequence obtained by one of the above methods is used generally by fusing it to a counter antigen or antibody by genetic engineering. A carrier-binding amino acid sequence may be expressively fused to the N-terminus or C-terminus of a counter antigen or antibody. A suitable spacer sequence may be inserted between them.  
           [0035]    A preferred spacer sequence is a sequence consisting of 3 to approximately 400 amino acids. Further, such a spacer may contain any amino acid. Most importantly, spacers would not interfere the interaction between the assay target and a counter antigen or antibody, and not prevent binding of the antigen or antibody to the carrier.  
           [0036]    The fusion of a carrier-binding peptide and a counter antigen or antibody can be isolated and purified by any method, as long as the activity of the antigen or antibody can be maintained.  
           [0037]    A step of immobilizing a counter antigen or antibody to a carrier can be achieved by contacting a fusion of a counter antigen or antibody and carrier-binding amino acid sequence with a carrier in an aqueous solvent.  
           [0038]    The composition of an aqueous solvent is not particularly limited in this step, and various buffer solutions can be used. Preferably, buffers used in biochemistry can be used, such as acetate buffer, phosphate buffer, potassium phosphate buffer, 3-(N-morpholino)propanesulfonic acid (MOPS) buffer, N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS) buffer, tris HCl buffer, glycine buffer, or 2-(cyclohexylamino)ethanesulfonic acid (CHES) buffer. The buffer solution can be used in ordinary concentrations of 5 mM to 1.0 M, preferably, 10 to 200 mM. pH is controlled at 5.5 to 9.0, preferably at 7.0 to 8.5, but depending on conditions applied, pH is not limited to this range.  
           [0039]    In order to retain the dispersed state of a carrier in an aqueous solvent, a suitable surfactant may be added, as long as the type and concentration of the additive surfactant do not hinder the subsequent steps. Examples of such a surfactant include anionic surfactants such as sodium oleate, sodium dodecylsulfonate, sodium dodecylsulfate, sodium N-dodecylsarcosinate, sodium cholate, sodium deoxycholate or sodium taurodeoxycholate; cationic surfactants such as cetyl trimethyl ammonium bromide or dodecyl pyridium chloride; ampholytic surfactants such as 3-[(chloamidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS), 3-[(3-chloamidopropyl)dimehyl-ammonio]-2-hydroxy-1-propanesulfonate (CHAPSO), palmitoyl lysolecithin or dodecyl-β-alanine; nonionic surfactants such as octyl glycoside, octyl thioglycoside, heptyl thioglycoside, decanoyl-N-methyl glucamide (MEGA-10), polyoxyethylene dodecyl ether (Brij, Lubrol), polyoxyethylene-i-octylphenyl ether (Triton X), polyoxyethylene nonylphenyl ether (Nonidet P-40, Triton N), polyoxyethylene fatty acid ester (Span) or polyoxyethylene sorbitol ester (Tween); and other surfactants.  
           [0040]    Furthermore, in order to retain the dispersed state of a powdery carrier in an aqueous solvent, a suitable auxiliary solvent may be added, as long as the type and concentration of the additive auxiliary solvent do not hinder the subsequent steps. The auxiliary solvent can be selected from the group consisting of straight chain aliphatic hydrocarbons such as hexane, monohydric alcohols such as methanol or ethanol, polyhydric alcohols such as glycerol, fatty acid ethers, and carboxylic acid ethers, derivatives thereof, and combinations thereof.  
           [0041]    As described above, the above fusion counter antigen or antibody is immobilized to a carrier by mixing the carrier with the fusion in a certain aqueous solvent at a certain concentration. In this case, a reactor is desirably shaken or stirred at a suitable strength so that the fusion antigen or antibody can bind uniformly to the surface of the carrier.  
           [0042]    The immobilized amount can be determined by, for example, applying to a carrier a solution of a fused antigen or antibody of a known concentration for immobilization, and determining the protein concentration of the solution after immobilization reaction to calculate the immobilized amount by subtraction.  
           [0043]    The immobilized antigen or antibody produced as described above can be used as it is, but it may be subjected to freeze-drying etc. before use.  
           [0044]    Time of the immobilization treatment for an antigen or antibody is desirably 1 minute to 24 hours, and more desirably 10 minutes to 1 hour. Excessively long treatment is not preferable because the activity of the antigen or antibody may decrease.  
           [0045]    In the present invention, additives such as an organic solvent, pigment, dye, indicator, surfactant, antiseptic, protective or inorganic salts may be used with the above components, according to necessity.  
           [0046]    According to the present invention, an antigen or antibody can be immobilized efficiently on the surface of a carrier, and the production process is thereby extremely efficient.  
           [0047]    When a color material such as a pigment is used as the carrier, the fusion antigen or antibody described above can be used as an assay reagent of high reliability for clinical laboratory tests, environmental and food analysis, because of easy visual determination as well as high quantitativity. 
       
    
    
     EXAMPLES  
       [0048]    The present invention is further described in the following Examples. These Examples are provided only for illustrating embodiments of the present invention, and are not intended to limit the technical scope of the present invention.  
         [0049]    Although a pigment was used as a carrier in the following Examples, the carrier is not limited thereto, but any known carrier of an antigen or antibody that is used in the conventional antigen-antibody reaction can be used with no particular limits.  
       Reference Example 1  
       [0050]    Obtainment of Antigen Protein to Hepatitis C Virus Antibody  
         [0051]    To 0.5 ml of human serum (Hepatitis B virus negative, GPT higher than 100 U), 2.5 ml of a guanidium thiocyanate solution (4 M guanidium thiocyanate, 10 mM EDTA, 0.1 M 2-mercaptomethanol, 2% sarcosyl, 50 mM Tris-HCl, pH 7.6) was added, and then total RNA in the serum was extracted by phenol/chloroform extraction, and purified by ethanol precipitation using glycogen as a carrier. Thereafter, cDNA was prepared from the obtained RNA using random hexamers as primers according to the method of Okamoto et al. (Japan J. Exp. Med., 60(3), 167-177, 1990) with a cDNA synthesis system (Boehringer Mannheim). Using this cDNA as a template, a DNA fragment of interest was amplified by PCR. The 5′-terminus of the amplified DNA was phosphorylated with T4 polynucleotide kinase, and then cloned by ligating it to plasmid pUC18 (Amersham Pharmacia Biotech) digested with a restriction enzyme SmaI. The HCV cDNA cloned into the plasmid was sequenced using Sequenase Sequence kit (United States Biochemical). From the obtained nucleotide sequence, a portion encoding an antigen protein NS4 of interest was selected. That portion was inserted into the SmaI-cleaved site of the plasmid pUC18 according to the conventional method so as to construct a plasmid pUC18-NS.  
       Example 1  
       [0052]    Obtainment of Amino Acid Sequence Capable of Binding to Copper Phthalocyanine  
         [0053]    (1) Copper phthalocyanine (α form, Tokyo Kasei Kogyo Co., Ltd.) was suspended in a TBS buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl) containing 0.1% Tween-20, at a concentration of 5 mg/ml. 10 μl of the suspension was put in an Eppendorf tube, and 990 μl of a TBST buffer (a TBS buffer+0.1% Tween-20) was further added thereto for dilution.  
         [0054]    (2) Approximately 4×10 10  pfu of Ph. D. −12 phage display peptide library (New England BioLabs) was added to the tube, and was left to stand at 25° C. for 10 minutes.  
         [0055]    (3) The tube was subjected to centrifugation (20,630×g, 5 minutes). Thereafter, the supernatant was discarded, and the pigment was recovered as a precipitate. The recovered pigment was suspended in a TBST buffer again, and washed 10 times by repeating centrifugation.  
         [0056]    (4) 100 μl of an elution buffer (0.2 M Glycine-HCl, pH 2.2, 1 mg/ml BSA) was added thereto and the suspension was left to stand for 1 minute, and then centrifuged (20,630×g, 5 minutes). The obtained supernatant was transferred into another Eppendorf tube, to which 15 μl of 1 M Tris-HCl (pH 9.1) was added for neutralization. Thus the eluted phages were obtained.  
         [0057]    (5) The eluted phages were used to infect  E. coli  ER2537 (New England BioLabs) cells in its early logarithmic growth phase were infected to be amplified therein. Culture was carried out at 37° C. for 4.5 hours. Thereafter, the amplified phages were separated from the cells by centrifugation, and then purified by precipitation with polyethylene glycol. The thus amplified and purified phages were then suspended in a TBS buffer, and the titer was determined by using an appropriate dilution series to infect  E. coli  cells.  
         [0058]    (6) The above steps (1) to (5) were repeated three times using amplified phages. However, the concentration of Tween-20 in the TBS buffer was increased to 0.5% to establish more strict washing conditions.  
         [0059]    From the second cycle, the same operations were carried out using an Eppendorf tube not containing pigment as a control. The titer of the eluted phages in each cycle is shown in Table 1.  
                                                                   TABLE 1                           Titer of phage eluted in each cycle                    Binding                       Stock   to   Binding to           solution   control   phthalocyanine           (A)   (B)   (C)   C/A   C/B                        1st cycle   4.0 × 10 11         1.2 × 10 6     3.0 × 10 −6             2nd cycle   1.6 × 10 11     1.1 × 10 5     1.7 × 10 5     1.1 × 10 −5     1       3rd cycle   2.0 × 10 11     1.6 × 10 5     3.0 × 10 8     1.5 × 10 −3     1800       4th cycle   1.7 × 10 11     2.7 × 10 6     5.3 × 10 9     3.1 × 10 −2     2000                          
 
         [0060]    For cloning of the finally eluted phages, excessive  E. coli  cells were infected with the phages. ssDNA was then prepared from each clone amplified in  E. coli . Thereafter, the random region was sequenced to determine the amino acid sequence of the displayed peptide, whereby the amino acid sequence capable of binding to copper phthalocyanine was determined for each clone. The determined amino acid sequences and their frequencies are shown in Table 2.  
                             TABLE 2                           Determined amino acid sequences and their frequencies                Numbers   Frequencies       Determined amino acid sequences   (A)   (A/36)               Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-   6   0.17       His-Ser-His       (SEQ ID NO 1)       Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-   6   0.17       Arg-Trp-Glu       (SEQ ID NO 2)       Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-   4   0.11       Ala-Leu-Ser       (SEQ ID NO 3)       Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-   3   0.08       Pro-Trp-Pro       (SEQ ID NO 4)       Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-   3   0.08       Thr-Pro-Thr       (SEQ ID NO 5)       Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-   3   0.08       Trp-Trp-Phe       (SEQ ID NO 6)       Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-   3   0.08       Ile-Glu-Pro       (SEQ ID NO 7)       Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-   1   0.02       Tyr-Gly-Val       (SEQ ID NO 8)       Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-   1   0.02       Leu-Ala-Gln       (SEQ ID NO 9)       Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-   1   0.02       Ser-Ser-Ser       (SEQ ID NO 10)       Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-   1   0.02       Gln-Ala-Thr       (SEQ ID NO 11)       Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-   1   0.02       Thr-Pro-Trp       (SEQ ID NO 12)       Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-   1   0.02       Thr-Ser-Val       (SEQ ID NO 13)       Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-   1   0.02       Thr-Val-His       (SEQ ID NO 14)       Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-   1   0.02       His-His-Val       (SEQ ID NO 15)                  
 
       Example 2  
       [0061]    Obtainment of Amino Acid Sequence Capable of Binding to Carbon Black  
         [0062]    (1) Carbon black (Sigma-Aldrich Japan, K.K.) was suspended in a TBS buffer (50 mM Tris-HCl with pH 7.5, 150 mM NaCl) containing 0.1% Tween-20 to a concentration of 5 mg/ml. 10 μl of the suspension was put in an Eppendorf tube, and 990 μl of a TBST buffer (a TBS buffer+0.1% Tween-20) was further added thereto for dilution.  
         [0063]    (2) Approximately 4×10 10  pfu of Ph. D. −12 phage display peptide library (New England BioLabs) was added to the tube, and was left to stand at 25° C. for 10 minutes.  
         [0064]    (3) The tube was subjected to centrifugation (20, 630×g, 5 minutes). Thereafter, the supernatant was discarded, and the pigment was recovered as a precipitate. The recovered pigment was suspended in a TBST buffer again, and washed 10 times by repeating centrifugation.  
         [0065]    (4) 100 μl of an elution buffer (0.2 M Glycine-HCl, pH 2.2, 1 mg/ml BSA) was added thereto and left to stand for 1 minute, and then centrifuged (20,630×g, 5 minutes). The obtained supernatant was transferred into another Eppendorf tube, to which 15 μl of 1 M Tris-HCl (pH 9.1) was added for neutralization. Thus the eluted phages were obtained.  
         [0066]    (5) The eluted phages were used to infect  E. coli  ER2537 (New England BioLabs) cells in its early logarithmic growth phase were infected to be amplified therein. Culture was carried out at 37° C. for 4.5 hours. Thereafter, the amplified phages were separated from the cells by centrifugation, and then purified by precipitation with polyethylene glycol. The thus amplified and purified phages were then suspended in a TBS buffer, and the titer was determined by using an appropriate dilution series and  E. coli  cells.  
         [0067]    (6) The above steps (1) to (5) were repeated four times using amplified phages. However, the concentration of Tween-20 in the TBS buffer was increased to 0.5% to establish more strict washing conditions.  
         [0068]    From the second cycle, the same operations were carried out using an Eppendorf tube not containing pigment as a control. The titer of the eluted phages in each cycle is shown in Table 3.  
         [0069]    The titer of the eluted phage in each cycle is shown in Table 3.  
                                                                   TABLE 3                           Titer of phage eluted in each cycle                    Binding   Binding                   Stock   to   to carbon           solution   control   black           (A)   (B)   (C)   C/A   C/B                        1st   4.0 × 10 11         8.9 × 10 6     2.2 × 10 −5             cycle       2nd   1.6 × 10 11     1.1 × 10 5     3.8 × 10 6     2.4 × 10 −5     35       cycle       3rd   2.0 × 10 11     1.6 × 10 5     6.0 × 10 6     3.0 × 10 −5     40       cycle       4th   1.7 × 10 11     1.1 × 10 6     1.5 × 10 8     8.8 × 10 −4     140       cycle       5th   1.9 × 10 11     2.0 × 10 6     2.7 × 10 9     1.4 × 10 −2     1400       cycle                          
 
         [0070]    For cloning of the finally eluted phages, excessive  E. coli  cells were infected with the phages. ssDNA was then prepared from each clone amplified in  E. coli . Thereafter, the random region was sequenced to determine the amino acid sequence of the displayed peptide, whereby the amino acid sequence capable of binding to carbon black was determined for each clone. The obtained amino acid sequences and their frequencies are shown in Table 4.  
                                                       TABLE 4                           Determined amino acid sequences and their frequen-           cies                Num-   Fre-               bers   quencies       Determined amino acid sequences   (2)   (A/38)                    Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-   4   0.10           Pro-Ala-Ser               (SEQ ID NO 16)                       Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-   3   0.08       His-Gln-Pro               (SEQ ID NO 17)                       Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-   2   0.05       Ser-His-His               (SEQ ID NO 18)                       Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-   2   0.05       Asp-Val-Tyr               (SEQ ID NO 19)                       Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-   2   0.05       Asn-Thr-Thr               (SEQ ID NO 20)                       Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Arg-   2   0.05       Tyr-Pro-Val               (SEQ ID NO 21)                       Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-   2   0.05       Ala-Ala-Val               (SEQ ID NO 22)                       Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-   2   0.05       Gln-Pro-Pro               (SEQ ID NO 23)                       Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-   2   0.05       Ile-Thr-Lys               (SEQ ID NO 24)                       His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-   2   0.05       Pro-Gln-Phe               (SEQ ID NO 25)                       Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-   1   0.03       Phe-Pro-Ile               (SEQ ID NO 26)                       Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-   1   0.03       Pro-Leu-Thr               (SEQ ID NO 27)                       Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-   1   0.03       Trp-Tyr-Arg               (SEQ ID NO 28)                       Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-   1   0.03       Val-His-Ser               (SEQ ID NO 29)                       Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-   1   0.03       Pro-Gln-Val               (SEQ ID NO 30)                       Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-   1   0.03       Ala-Thr-Val               (SEQ ID NO 31)                       Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-   1   0.03       Tyr-Tyr-Tyr               (SEQ ID NO 32)                       Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-   1   0.03       Arg-Ser-Val               (SEQ ID NO 33)                       Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-   1   0.03       Ser-Asn-Pro               (SEQ ID NO 34)                       Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-   1   0.03       Tyr-Leu-Arg               (SEQ ID NO 35)                       His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-   1   0.03       Leu-Ala-Pro               (SEQ ID NO 36)                       Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-   1   0.03       Leu-Ile-Ala               (SEQ ID NO 37)                       Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-   1   0.03       Pro-Pro-Phe               (SEQ ID NO 38)                       His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-   1   0.03       Thr-Ala-Ser               (SEQ ID NO 39)                       Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-   1   0.03       Pro-Ser-Ile               (SEQ ID NO 40)                  
 
       Example 3  
       [0071]    Production of Antigen Protein Capable of Binding to Copper Phthalocyanine  
         [0072]    With an upstream primer (5′-TTCACAGGATCCACTGAGCTCGATGCC CAC-3′) and an downstream primer (5′-GATCTGGGCTCGAGCCGACTAGTA GTCGCT-3′) for a nucleotide sequence encoding the antigen protein NS4, PCR was carried out using the plasmid pUC18-NS prepared in Reference Example as a template. The obtained DNA fragment had BamHI/SacI restriction site in the upstream region and SpeI/XhoI restriction site in the downstream region and the antigen protein NS4 gene between them.  
         [0073]    The purified PCR-amplified product was digested with BamHI and XhoI, and the digest was then inserted into the corresponding site of plasmid pGEX-6P-1 (Amersham Pharmacia Biotech), so as to obtain a vector pGEX-NS.  
         [0074]    Then,  E. coli  expression vectors that can express each of the binding amino acid sequences (SEQ ID NOS: 1 to 15) of Example 1 fused to the N-terminus of the antigen protein NS4 via a spacer sequence GS were prepared as follows. A set of synthesized double-stranded oligonucleotides shown in Table 5 below was prepared as DNA encoding these amino acid sequences.  
                                               TABLE 5                           Synthesized DNA used in expression of each amino           acid sequence            Amino               acid           sequence           No.   Nucleotide sequence of synthesized DNA                    1   5′-               GATCCAAATATGATAGCCGTCATCTGCATACCCATAGCCATG           AGCT-3′                   5′-CATGGCTATGGGTATGCACATGACGGCTATCATATTTG-           3′               2   5′-           GATCCCCGAACCGTCTGGGCCGTCGTCCGGTGCGTTGGGAAG           AGCT-3′                   5′-CTTCCCAACGCACCGGACGACGGCCCAGACGGTTCGGG-           3′               3   5′-           GATCCAAATGCTGCTATTATGATCATAGCCATGCGCTGAGCG           AGCT-3′                   5′-CGCTCAGCGCATGGCTATGATCATAATAGCAGCATTTG-           3′               4   5′-           GATCCGAATATCTGAGCGCGATTGTGGCGGGCCCGTGGCCGG           AGCT-3′                   5′-CCGGCCACGGGCCCGCCACAATCGCGCTCAGATATTCG-           3′               5   5′-           GATCCAAACTGTGGATTCTGGAACCGACCGTGACCCCGACCG           AGCT-3′                   5′-CGGTCGGGGTCACGGTCGGTTCCAGAATCCACAGTTTG-           3′               6   5′-           GATCCCAGAGCAACCTGAAAGTGATTCCGAGCTGGTGGTTTG           AGCT-3′                   5′-CAAACCACCAGCTCGGAATCACTTTCAGGTTGCTCTGG-           3′               7   5′-           GATCCTGGATTCCGCCGCAGTGGAGCCGTCTGATTGAACCGG           AGCT-3′                   5′-CCGGTTCAATCAGACGGCTCCACTGCGGCGGAATCCAG-           3′               8   5′-           GATCCGATCATCCGCAGGCGAAACCGAACTGGTATGGCGTGG           AGCT-3′                   5′-CCACGCCATACCAGTTCGGTTTCGCCTGCGGATGATCG-           3′               9   5′-           GATCCGGCCTGCCGCCGTATAGCCCGCATCGTCTGGCGCAGG           AGCT-3′                   5′-CCTGCGCCAGACGATGCGCGCTATACGCCGGCAGGCCG-           3′               10   5′-           GATCCAAACTGACCACCCAGTATATGGCGCGTAGCAGCAGCG           AGCT-3′                   5′-CGCTGCTGCTACGCGCCATATACTGGGTGGTCAGTTTG-           3′               11   5′-           GATCCAAAGTGTGGATGCTGCCGCCGCTGCCGCAGGCGACCG           AGCT-3′                   5′-CGGTCGCCTGCGGCAGCGGCGGCAGCATCCACACTTTG-           3′               12   5′-           GATCCAACGTGACCAGCACCGCGTTTATTGATACCCCGTGGG           AGCT-3′                   5′-CCCACGGGGTATCAATAAACGCGCTGCTGGTCACGTTG-           3′               13   5′-           GATCCCCTCTGAACCTGGATATTATTGCGGTGACCAGCGTGG           AGCT-3′                   5′-CCACGCTGGTCACCGCAATAATATCCAGGTTCAGACGG-           3′               14   5′-           GATCCACCCTGCCGAGCCCGCTGGCGCTGCTGACCGTGCATG           AGCT-3′                   5′-CATGCACGGTCAGCAGCGCCAGCGGGCTCGGCAGGGTG-           3′               15   5′-           GATCCACCAACCGTCATAACCCCCATCATCTGCATCATGTGG           AGCT-3′                   5′-CCACATGATGCAGATGATGCGGGTTATGACGGTTGGTG-           3′                          
 
         [0075]    Two DNA fragments were synthesized for each amino acid sequence as shown in Table 5, and phosphorylated with T4 polynucleotide kinase (Gibco) according to the instructions of the manufacturers. Subsequently, the two synthesized DNA fragments were mixed in equimolar, and the mixture was heated at 80° C. for 5 minutes and slowly cooled to room temperature, so as to obtain a double-stranded DNA fragment. The obtained double-stranded DNA fragment was directly used in the following cloning step.  
         [0076]    The plasmid pGEX-NS was digested with BamHI or SacI, and the above double-stranded DNA fragment was inserted thereinto. A host microorganism,  E. coli  JM109 was transformed using this vector, so as to obtain a transformant that expresses a binding amino acid sequence-NS4-glutathione-S-transferase (GST) fusion protein. The transformed strain was confirmed by determining the nucleotide sequence of the insert by sequencing using pGEX 5′ Sequencing Primer (Amersham Pharmacia Biotech) and plasmid DNA prepared using Miniprep (Wizard Minipreps DNA Purification Systems (PROMEGA)) as a template.  
         [0077]    The obtained strain was precultured overnight in 10 ml LB-Amp medium, and 0.1 ml of the preculture was transferred to fresh 10 ml LB-Amp medium for shake culture of 170 rpm at 37° C. for 3 hours. Thereafter, IPTG was added thereto (final concentration: 1 mM), and culture was continued at 37° C. for 4 to 12 hours.  
         [0078]    IPTG-induced  E. coli  was collected (8,000×g, 2 minutes, 4° C.) and resuspended in a 1/10 amount of 4° C. PBS. The cells were disrupted by freezing-thawing and sonication, and centrifuged (8,000×g, 10 minutes, 4° C.) to remove solid matters. The presence of an expressed protein of interest in the supernatant was confirmed by SDS-PAGE, and thereafter, the expressed GST fusion protein was purified using Glutathione Sepharose 4B (Glutathione Sepharose 4B beads; Amersham Pharmacia Biotech).  
         [0079]    Beforehand, the glutathione sepharose was treated for controlling nonspecific adsorption as follows: Glutathione sepharose was washed three times with an equal amount of PBS using centrifugation (8,000×g, 1 minute, 4° C.), to which an equal amount of 4% BSA-containing PBS was added, and then left to stand at 4° C. for 1 hour. After the treatment, the resulting product was washed twice with an equal amount of PBS, and it was then resuspended in a 1/2 amount of PBS.  
         [0080]    40 μl of the pretreated glutathione sepharose was added to 1 ml of a cell-free extract, and the mixture was gently stirred at 4° C. Thus, the GST fusion protein was adsorbed on the glutathione sepharose.  
         [0081]    After the adsorption, the glutathione sepharose was recovered by centrifugation (8,000×g, 1 minute, 4° C.), and washed three times with 400 μl of PBS. Thereafter, 40 μl of 10 mM glutathione was added thereto, and the mixture was stirred at 4° C. for 1 hour to elute the adsorbed GST fusion protein. The supernatant was recovered by centrifugation (8,000×g, 2 minutes, 4° C.), and dialyzed against PBS so as to purify the GST fusion protein. It was confirmed that the purified protein showed a single band on SDS-PAGE.  
         [0082]    500 μg of each GST fusion protein was digested with PreScission protease (Amersham Pharmacia Biotech, 5 U), and the digest was passed through glutathione sepharose to remove the PreScission protease and the GST. The flow-through fraction was applied to a Sephadex G200 column equilibrated with PBS, so as to obtain the final purified product of the expression protein. It was confirmed that the final purified protein showed a single band on SDS-PAGE.  
       Example 4  
       [0083]    Production of Antigen Protein Capable of Binding to Carbon Black  
         [0084]    With an upstream primer (5′-TTCACAGGATCCACTGAGCTCGATGCC CAC-3′) and an downstream primer (5′-GATCTGGGCTCGAGCCGACTAGTA GTCGCT-3′) for a nucleotide sequence encoding the antigen protein NS4, PCR was carried out using the plasmid pUC18-NS prepared in Reference Example as a template. The obtained DNA fragment had BamHI and SacI restriction site in the upstream region and SpeI and XhoI restriction site in the downstream region and the antigen protein NS4 gene between them.  
         [0085]    The purified PCR-amplified product was digested with BamHI and XhoI, and the digest was then inserted into the corresponding site of plasmid pGEX-6P-1 (Amersham Pharmacia Biotech), so as to obtain a vector pGEX-NS.  
         [0086]    Then,  E. coli  expression vectors that can express each of the binding amino acid sequences (SEQ ID NOS: 16 to 40) of Example 2 fused to the N-terminus of the antigen protein NS4 via a spacer sequence GS were prepared as follows. A set of synthesized double-stranded oligonucleotides shown in Table 6 below was prepared as DNA encoding these amino acid sequences.  
                                               TABLE 6                           Synthesized DNA sets used in expression of each a-           mino acid sequence            Amino               acid           se-           quence           No.   Nucleotide sequence of synthesized DNA                    16   5′-               GATCCTGGCCGCATGCGTGGAAAGTGTGGTGGCCGGCGAGCGAG           CT-3′                   5′-CGCTCGCCGGCCACCACACTTTCCACGCATGCGGCCAG-3′               17   5′-           GATCCAACTGGTGGTGGCCGCCGTATATTCGTCATCAGCCGGAG           CT-3′                   5′-CCGGCTGATGACGAATATACGGCGGCCACCACCAGTTG-3′               18   5′-           GATCCTGGCATTGGAGCTGGACCCCGTGGCCGAGCCATCATGAG           CT-3′                   5′-CATGATGGCTCCGCCACGGGGTCCAGCTCCAATGCCAG-3′               19   5′-           GATCCTGGCCGTGGGCGTGGCATCCGAGCCGTGATGTGTATGAG           CT-3′                   5′-CATACACATCACGGCTCGGATGCCACGCCCACGGCCAG-3′               20   5′-           GATCCTGGCATGGCTATTGGTATAGCAACCTGAACACCACCGAG           CT-3′                   5′-CGGTGGTGTTCACGTTGCTATACCAATAGCCATGCCAG-3′               21   5′-           GATCCTGGTGGACCCCGTGGATGAGCCATGCGTATCCGGTGGAG           CT-3                   5′-CCACCGGATACGCATGGCTCATCCACGGGGTCCACCAG-3               22   5′-           GATCCTGGCCGAACCCGTATTGGGGCTGGTTTGCGGCGGTGGAG           CT-3′                   5′-CCACCGCCGCAAACCAGCCCCAATACGGGTTCGGCCAG-3               23   5′-           GATCCACCAGCTGGCATACCTGGTGGTGGCGTCAGCCGCCGGAG           CT-3                   5′-CCGGCGGCTGACGCCACCACCAGGTATGCCAGCTGGTG-3               24   5′-           GATCCAACGCGTGGCATAAATATTGGTGGCCGATTACCAAAGAG           CT-3′                   5′-CTTTGGTAATCGGCCACCAATATTTATGCCACGCGTTG-3′               25   5′-           GATCCCATCCGAACAACGATTGGAGCAAAGCGCCGCAGTTTGAG           CT-3′                   5′-CAAACTGCGGCGCTTTGCTCCAATCGTTGTTCGGATGG-3′               26   5′-           GATCCTGGTGGACCCCGCAGCCGTGGTGGAGCTTTCCGATTGAG           CT-3′                   5′-CAATCGGAAAGCTCCACCACGGCTGCGGGGTCCACCAG-3′               27   5′-           GATCCTGGCCGCATACCAGCTGGTGGCAGACCCCGCTGACCGAG           CT-3                   5′-CGGTCAGCGGGGTCTGCCACCAGCTGGTATGCGGCCAG-3′               28   5′-           GATCCTGGCATGTGAACTGGGATCCGATGGCGTGGTATCGTGAG           CT-3′                   5′-CACGATACCACGCCATCGGATCCCAGTTCACATGCCAG-3′               29   5′-           GATCCAGCTGGCCGTGGTGGACCGCGTATCGTGTGCATAGCGAG           CT-3′                   5′-CGCTATGCACACGATACGCGGTCCACCACGGCCAGCTG-3               30   5′-           GATCCTGGCATAGCAACTGGTATCAGAGCATTCCGCAGGTGGAG           CT-3′                   5′-CCACCTGCGGAATGCTCTGATACCAGTTGCTATGCCAG-3′               31   5′-           GATCCGGCTATTGGCCGTGGAAATTTGAACATGCGACCGTGGAG           CT-3′                   5′-CCACGGTCGCATGTTCAAATTTCCACGGCCAATAGCCG-3′               32   5′-           GATCCGCGTGGTGGCCGACCACCTTTCCGCCGTATTATTATGAG           CT-3′                   5′-CATAATAATACGGCGGAAAGGTGGTCGGCCACCACGCG-3′               33   5′-           GATCCAACCCGTGGTGGAGCCATTATTATCCGCGTAGCGTGGAG           CT-3′                   5′-CCACGCTACGCCCATAATAATGGCTCCACCACGGGTTG-3′               34   5′-           GATCCTGGCCGCATAACTATCCGCTGAACCATAGCAACCCGGAG           CT-3′                   5′-CCGGGTTGCTATGGTTCAGCGGATAGTTATGCGGCCAG-3′               35   5′-           GATCCACCTGGGCGCATCCGCTGGAAAGCGATTATCTGCGTGAG           CT-3′                   5′-CACGCAGATAATCGCTTTCCAGCGGATGCGCCCAGGTG-3′               36   5′-           GATCCCATACCTATTATCATGATGGCTGGCGTCTGGCGCCGGAG           CT-3′                   5′-CCGGCGCCAGACGCCAGCCATCATGATAATAGGTATGG-3′               37   5′-           GATCCACCTTTGTGCAGACCCCGCTGAGCCATCTGATTCCGGAG           CT-3′                   5′-CCGCAATCAGATGGCTCAGCGGGGTCTGCACAAAGGTG-3               38   5′-           GATCCCGTGTGCCGCCGAGCAAACTGACCCGTCCGCCGTTTGAG           CT-3′                   5′-CAAACGGCGGACGGGTCAGTTTGCTCGGCGGCACACGG-3′               39   5′-           GATCCCATAGCATTTATAGCGTGACCCCGAGCACCGCGAGCGAG           CT-3′                   5′-CGCTCGCGGTGCTCGGGGTCACGCTATAAATGCTATGG-3′               40   5′-           GATCCCTGAACACCCAGAACCATGCGCCGCTGCCGAGCATTGAG           CT-3′                   5′-CAATGCTCGGCAGCGGCGCATGGTTCTGGGTGTTCAGG-3′                          
 
         [0087]    Two DNA fragments were synthesized for each amino acid sequence as shown in Table 5, and phosphorylated with T4 polynucleotide kinase (Gibco) according to the instructions of the manufacturers. Subsequently, the two synthesized DNA fragments were mixed in equimolar, and the mixture was heated at 80° C. for 5 minutes and slowly cooled to room temperature, so as to obtain a double-stranded DNA fragment. The obtained double-stranded DNA fragment was directly used in the following cloning step.  
         [0088]    The plasmid pGEX-NS was digested with BamHI or SacI, and the above double-stranded DNA fragment was inserted thereinto. A host microorganism,  E. coli  JM109 was transformed using this vector, so as to obtain a transformant that expresses a binding amino acid sequence-NS4-glutathione-S-transferase (GST) fusion protein. The transformant was confirmed by determining the nucleotide sequence of the insert by sequencing using pGEX 5′ Sequencing Primer (Amersham Pharmacia Biotech) and plasmid DNA prepared using Miniprep (Wizard Minipreps DNA Purification Systems (PROMEGA)) as a template.  
         [0089]    The obtained strain was precultured overnight in 10 ml LB-Amp medium, and 0.1 ml of the preculture was transferred to fresh 10 ml LB-Amp medium for shake culture of 170 rpm at 37° C. for 3 hours. Thereafter, IPTG was added thereto (final concentration: 1 mM), and culture was continued at 37° C. for 4 to 12 hours.  
         [0090]    IPTG-induced  E. coli  was collected (8,000×g, 2 minutes, 4° C.) and resuspended in a {fraction (1/10)} amount of 4° C. PBS. The cells were disrupted by freezing-thawing and sonication, and centrifuged (8,000×g, 10 minutes, 4° C.) to remove solid matters. The presence of an expressed protein of interest in the supernatant was confirmed by SDS-PAGE, and thereafter, the expressed GST fusion protein was purified using Glutathione Sepharose 4B (Glutathione Sepharose 4B beads; Amersham Pharmacia Biotech).  
         [0091]    Beforehand, the glutathione sepharose was treated for controlling nonspecific adsorption as follows: Glutathione sepharose was washed three times with an equal amount of PBS using centrifugation (8,000×g, 1 minute, 4° C.), to which an equal amount of 4% BSA-containing PBS was added, and then left to stand at 4° C. for 1 hour. After the treatment, the resulting product was washed twice with an equal amount of PBS, and it was then resuspended in a ½ amount of PBS.  
         [0092]    40 μl of the pretreated glutathione sepharose was added to 1 ml of a cell-free extract, and the mixture was gently stirred at 4° C. Thus, the GST fusion protein was adsorbed on the glutathione sepharose.  
         [0093]    After the adsorption, the glutathione sepharose was recovered by centrifugation (8,000×g, 1 minute, 4° C.), and washed three times with 400 μl of PBS. Thereafter, 40 μl of 10 mM glutathione was added thereto, and the mixture was stirred at 4° C. for 1 hour to elute the adsorbed GST fusion protein. The supernatant was recovered by centrifugation (8,000×g, 2 minutes, 4° C.), and dialyzed against PBS so as to purify the GST fusion protein. It was confirmed that the purified protein showed a single band on SDS-PAGE.  
         [0094]    500 μg of each GST fusion protein was digested with PreScission protease (Amersham Pharmacia Biotech, 5 U), and the digest was passed through glutathione sepharose to remove the PreScission protease and the GST. The flow-through fraction was applied to a Sephadex G200 column equilibrated with PBS, so as to obtain the final purified product of the expression protein. It was confirmed that the final purified protein showed a single band on SDS-PAGE.  
       Example 5  
       [0095]    Production of Antigen Protein Capable of Binding to Copper Phthalocyanine  
         [0096]    Two types of amino acid sequences capable of binding to copper phthalocyanine, Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1) and Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2), are connected in tandem in this order via a spacer sequence (Gly-Gly-Gly-Ser-Gly-Gly-Gly-Ser), so as to obtain a sequence Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Ser-Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 41). Then, an  E. coli  expression vector was constructed as described below, which expresses the obtained amino acid sequence via the spacer sequence GS such that the amino acid sequence is fused with the N-terminus of the antigen protein NS4. DNA encoding this amino acid sequence was obtained as a double-stranded DNA fragment as follows: each of two types of synthetic oligonucleotides, 5′ 
                               5′-   (SEQ ID NO:123)           GATCCAAATATGATAGCCGTCATCTGCATACCCATAGCCATGGCGGCGGCAGC               GGCGGCGGCAGCCCGAACCGTCTGGGCCGTCGTCCGGTGCGTTGGGAAGAGCT-       3′       and               5′-   (SEQ ID NO:124)       CTTCCCAACGCACCGGACGACGGCCCAGACGGTTCGGGCTGCCGCCGCCGCTG               CCGCCGCCATGGCTATGGGTATGCAGATGACGGCTATCATATTTG-3′          
 
         [0097]    ID NO:124) was phosphorylated with T4 polynucleotide kinase (Gibco), and mixed equimolar, and the mixture was heated at 80° C. for 5 minutes and then slowly cooled to room temperature. The obtained double-stranded DNA fragment was inserted into the BamHI/SacI site of plasmid pGEX-NS in the same manner as in Example 3. Using this vector,  E. coli  JM109 was transformed to obtain an expression transformant. In the same manner as in Example 3, an expression protein in which the amino acid sequence of SEQ ID NO 41 was fused at N-terminus of NS 4 was purified.  
       Example 6  
       [0098]    Production of Antigen Protein Capable of Binding to Carbon Black  
         [0099]    Two types of amino acid sequences capable of binding to carbon black, Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16) and Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17), are connected tandem in this order via a spacer sequence (Gly-Gly-Gly-Ser-Gly-Gly-Gly-Ser), so as to obtain a sequence Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Ser-Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 42). Then, an  E. coli  expression vector was constructed as described below, which expresses the obtained amino acid sequence via the spacer sequence GS such that the amino acid sequence is fused to the N-terminus of the antigen protein NS4. DNA encoding this amino acid sequence was obtained as a double-stranded DNA fragment as follows. Each of two types of synthetic oligonucleotides, 5′-GATCCTGGCCCGCATGCGTGGAAAGTGTGGTGGCCGGCGAGCGGCGGCGGCAGC GGCGGCGGCAGCAACTGGTGGTGGCCGCCGTATATTCGTCATCAGCCGGAGCT-3′ (SEQ ID NO:125) and 5′-CCGGCTGATGACGAATATACGGCGGCCACCACCAGTTGCTGCCGCCGCCGCTG CCGCCGCCGCTCGCCGGCCACCACACTTTCCACGCATGCGGCCAG-3′ (SEQ ID NO:126) was phosphorylated with T4 polynucleotide kinase (Gibco), and mixed in equimolar, the mixture was heated at 80° C. for 5 minutes and slowly cooled to room temperature. The obtained double-stranded DNA fragment was inserted into the BamHI/SacI site of plasmid PGEX-NS in the same manner as in Example 4. Using this vector,  E coli  JM109 was transformed to obtain an expression transformant. In the same manner as in Example 4, an expression protein in which the amino acid sequence of SEQ ID NO 42 was fused at N-terminus of NS4 was purified.  
       Comparative Example 1  
       [0100]    Production of Antigen Protein  
         [0101]    With an upstream primer (5′-TTCACAGGATCCACTGAGCTCGATGCC CAC-3′) and an downstream primer (5′-GATCTGGGCTCGAGCCGACTAGTA GTCGCT-3′) for a nucleotide sequence encoding the antigen protein NS4, PCR was carried out using the plasmid pUC18-NS prepared in Reference Example as a template. The obtained DNA fragment had BamHI and SacI restriction site in the upstream region and SpeI and XhoI restriction site in the downstream region and the antigen protein NS4 gene between them.  
         [0102]    The purified PCR-amplified product was digested with BamHI and XhoI, and the digest was then inserted into the corresponding site of plasmid pGEX-6P-1 (Amersham Pharmacia Biotech), so as to obtain a vector pGEX-NS. Using this vector,  E. coli  JM109 was transformed so as to obtain a transformed strain for the expression of an NS4-GST fusion protein. The transformant was confirmed by determining the nucleotide sequence of the insert by sequencing using PGEX 5′ Sequencing Primer (Amersham Pharmacia Biotech) and plasmid DNA prepared using Miniprep (Wizard Minipreps DNA Purification Systems (PROMEGA)) as a template.  
         [0103]    The obtained strain was precultured overnight in 10 ml LB-Amp medium, and 0.1 ml of the preculture was transferred to fresh 10 ml LB-Amp medium for shake culture of 170 rpm at 37° C. for 3 hours. Thereafter, IPTG was added thereto (final concentration: 1 mM), and culture was continued at 37° C. for 4 to 12 hours.  
         [0104]    IPTG-induced  E. coli  was collected (8,000×g, 2 minutes, 4° C.) and resuspended in a {fraction (1/10)} amount of 4° C. PBS. The cells were disrupted by freezing-thawing and sonication, and centrifuged (8,000×g, 10 minutes, 4° C.) to remove solid matters. The presence of an expressed protein of interest in the supernatant was confirmed by SDS-PAGE, and thereafter, the expressed GST fusion protein was purified using Glutathione Sepharose 4B (Glutathione Sepharose 4B beads; Amersham Pharmacia Biotech).  
         [0105]    Beforehand, the glutathione sepharose was treated for controlling nonspecific adsorption as follows: Glutathione sepharose was washed three times with an equal amount of PBS using centrifugation (8,000×g, 1 minute, 4° C.), to which an equal amount of 4% BSA-containing PBS was added, and then left to stand at 4° C. for 1 hour. After the treatment, the resulting product was washed twice with an equal amount of PBS, and it was then resuspended in a ½ amount of PBS.  
         [0106]    40 μl of the pretreated glutathione sepharose was added to 1 ml of a cell-free extract, and the mixture was gently stirred at 4° C. Thus, the GST fusion protein was adsorbed on the glutathione sepharose.  
         [0107]    After the adsorption, the glutathione sepharose was recovered by centrifugation (8,000×g, 1 minute, 4° C.), and washed three times with 400 μl of PBS. Thereafter, 40 μl of 10 mM glutathione was added thereto, and the mixture was stirred at 4° C. for 1 hour to elute the adsorbed GST fusion protein. The supernatant was recovered by centrifugation (8,000×g, 2 minutes, 4° C.), and dialyzed against PBS so as to purify the GST fusion protein. It was confirmed that the purified protein showed a single band on SDS-PAGE.  
         [0108]    500 μg of each GST fusion protein was digested with PreScission protease (Amersham Pharmacia Biotech, 5 U), and the digest was passed through glutathione sepharose to remove the PreScission protease and the GST. The flow-through fraction was applied to a Sephadex G200 column equilibrated with PBS, so as to obtain the final purified product of the expression protein. It was confirmed that the final purified protein showed a single band on SDS-PAGE.  
       Example 7  
       [0109]    Immobilization of Antigen Protein on Copper Phthalocyanine Particle  
         [0110]    Copper phthalocyanine particles were suspended in a TBS buffer containing 0.1% Tween-20 to a concentration of 0.5% (w/v). 10 ml of the suspension was placed in a Teflon (Commercial name) centrifugation tube, and 50 μg of the fusion protein prepared in Example 3 and 5, or the same amount of the protein prepared in Comparative Example 1 was added thereto followed by shaking at room temperature for 30 minutes. Centrifugal separation (10,000×g, 4° C., 10 minutes) was carried out, and copper phthalocyanine particles were recovered as a precipitate, so that the precipitate was separated from the supernatant containing antigen that did not bind to the copper phthalocyanine particles. The copper phthalocyanine particles were resuspended in a TBS buffer containing 0.1% Tween-20, and centrifugal separation was repeatedly carried out so as to wash the copper phthalocyanine particles. The protein concentration of the suspension of the washed copper phthalocyanine particles was determined with a Micro BCA Protein Assay Reagent (Pierce Chemical). The results are shown in Table 7.  
                                               TABLE 7                           Evaluation of binding ability of enzyme to copper       phthalocyanine                Amino acid sequence   Amount of protein           No.   (μg)                            Example 3   1   6           Example 3   2   6           Example 3   3   5           Example 3   4   5           Example 3   5   5           Example 3   6   5           Example 3   7   5           Example 3   8   5           Example 3   9   5           Example 3   10   5           Example 3   11   5           Example 3   12   5           Example 3   13   5           Example 3   14   4           Example 3   15   4           Example 5   41   11           Comparative   —   1           example 1                      
 
         [0111]    The concentration of the fusion proteins of Examples 3 and 5, with which a copper phthalocyanine binding sequence was fused, was higher than the concentration of the protein of Comparative Example 1. Thus, it was confirmed that an antigen protein can effectively be immobilized on the surface of a pigment by the fusion protein.  
       Example 8  
       [0112]    Immobilization of Antigen Protein on Carbon Black Article  
         [0113]    Carbon black particles were suspended in a TBS buffer containing 0.1% Tween-20, at a concentration of 0.5% (w/v). 10 ml of the suspension was placed in a Teflon (commercial name) centrifugation tube, and 50 μg of the fusion protein prepared in Example 4 and 6, or the same amount of the protein prepared in Comparative Example 1 was added thereto followed by shaking at room temperature for 30 minutes. Centrifugal separation (10,000×g, 4° C., 10 minutes) was carried out, and carbon black particles were recovered as a precipitate, so that the precipitate was separated from the supernatant containing antigen that did not bind to the carbon black particles. The carbon black particles were resuspended in a TBS buffer containing 0.1% Tween-20, and centrifugal separation was repeatedly carried out so as to wash the carbon black particles. The protein concentration of the suspension of the washed carbon black particles was determined with a Micro BCA Protein Assay Reagent (Pierce Chemical). The results are shown in Table 8.  
                                               TABLE 8                           Evaluation, of binding ability of enzyme to carbon       black                Amino acid sequence   Amount of protein           No.   (μg)                            Example 4   16   6           Example 4   17   6           Example 4   18   5           Example 4   19   5           Example 4   20   5           Example 4   21   5           Example 4   22   5           Example 4   23   5           Example 4   24   5           Example 4   25   5           Example 4   26   5           Example 4   27   5           Example 4   28   5           Example 4   29   4           Example 4   30   4           Example 4   31   4           Example 4   32   4           Example 4   33   4           Example 4   34   4           Example 4   35   4           Example 4   36   4           Example 4   37   4           Example 4   38   4           Example 4   39   4           Example 4   30   4           Example 6   42   15           Comparative   —   1           example 1                      
 
         [0114]    The concentration of the fusion proteins of Examples 4 and 6 containing a carbon black binding sequence was higher than the concentration of the protein of Comparative Example 1. Thus, it was confirmed that an antigen protein could be effectively immobilized on the surface of a pigment by the fusion protein.  
       Example 9  
       [0115]    Assay of HCV Antibody by Immunoagglutination Assay  
         [0116]    Pigment particles on which each of the fusion proteins produced in Examples 7 and 8 was immobilized, were suspended in a blocking buffer consisting of a 0.1 M potassium phosphate buffer (pH 6.5), 1.0% bovine serum albumin (Sigma-Aldrich Japan, K.K.) and 0.05% NaN 3 . The pigment particles were then recovered by centrifugal separation (10,000×g, 4° C., 10 minutes). This operation was repeated three times for washing. The obtained product was then suspended in 4 ml of a blocking buffer.  
         [0117]    The above prepared assay reagent was compared with a commercially available diagnostic agent for immunoagglutination assay (Ortho HCV Ab PAII manufactured by Ortho Diagnostic Systems Inc., hereinafter referred to as a “commercially available product”), using the serum of HCV antibody positive patients. The test was carried out according to the manual attached to the above commercially available product. Results are shown in Tables 9 and 10.  
                                                                                 TABLE 9                           Assay results of serum of HCV antibody positive       patients                Amino               acid           sequence   Dilution of serum (times)                No.   10,000   25,000   50,000   100,000                        Example 7   1   +   +   +   −           2   +   +   +   −           3   +   +   +   −           4   +   +   +   −           5   +   +   +   −           6   +   +   +   −           7   +   +   +   −           8   +   +   +   −           9   +   +   +   −           10   +   +   +   −           11   +   +   +   −           12   +   +   +   −           13   +   +   +   −           14   +   +   +   −           15   +   +   +   −           41   +   +   +   −       Commercially   −   +   +   −   −       available       product                          
 
         [0118]    [0118]                                                                                 TABLE 10                           Assay results of serum of Hepatitis C virus antibody       positive patients                Amino               acid           sequence   Dilution of serum (times)                No.   10,000   25,000   50,000   100,000                        Example 8   16   +   +   +   −           17   +   +   +   −           18   +   +   +   −           19   +   +   +   −           20   +   +   +   −           21   +   +   +   −           22   +   +   +   −           23   +   +   +   −           24   +   +   +   −           25   +   +   +   −           26   +   +   +   −           27   +   +   +   −           28   +   +   +   −           29   +   +   +   −           30   +   +   +   −           31   +   +   +   −           32   +   +   +   −           33   +   +   +   −           34   +   +   +   −           35   +   +   +   −           36   +   +   +   −           37   +   +   +   −           38   +   +   +   −           39   +   +   +   −           40   +   +   +   −           42   +   +   +   −       Commercially   −   +   +   −   −       available       product                            
         [0119]    From the results shown in Tables 9 and 10, it was found that the assay reagent of the present invention has sensitivity the same as or higher than the commercially available product. Moreover, since the assay reagent of the present invention contains a pigment as an insoluble carrier, the reagent is colored which enables extremely easy visual determination.  
         [0120]    It should be noted that the assay was carried out by visual observation in the above examples, but agglutination state may also be assayed by visual image recognition means such as CCD. In such a case, the assay of agglutination state can be carried out without using a color material as a carrier.  
     
       
       
         1 
         
           
             129  
           
           
             1  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            1 

Lys Tyr Asp Ser Arg His Leu His Thr His Ser His 
1               5                   10 

 
           
             2  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            2 

Pro Asn Arg Leu Gly Arg Arg Pro Val Arg Trp Glu 
1               5                   10 

 
           
             3  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            3 

Lys Cys Cys Tyr Tyr Asp His Ser His Ala Leu Ser 
1               5                   10 

 
           
             4  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            4 

Glu Tyr Leu Ser Ala Ile Val Ala Gly Pro Trp Pro 
1               5                   10 

 
           
             5  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            5 

Lys Leu Trp Ile Leu Glu Pro Thr Val Thr Pro Thr 
1               5                   10 

 
           
             6  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            6 

Gln Ser Asn Leu Lys Val Ile Pro Ser Trp Trp Phe 
1               5                   10 

 
           
             7  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            7 

Trp Ile Pro Pro Gln Trp Ser Arg Leu Ile Glu Pro 
1               5                   10 

 
           
             8  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            8 

Asp His Pro Gln Ala Lys Pro Asn Trp Tyr Gly Val 
1               5                   10 

 
           
             9  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            9 

Gly Leu Pro Pro Tyr Ser Pro His Arg Leu Ala Gln 
1               5                   10 

 
           
             10  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            10 

Lys Leu Thr Thr Gln Tyr Met Ala Arg Ser Ser Ser 
1               5                   10 

 
           
             11  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            11 

Lys Val Trp Met Leu Pro Pro Leu Pro Gln Ala Thr 
1               5                   10 

 
           
             12  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            12 

Asn Val Thr Ser Thr Ala Phe Ile Asp Thr Pro Trp 
1               5                   10 

 
           
             13  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            13 

Arg Leu Asn Leu Asp Ile Ile Ala Val Thr Ser Val 
1               5                   10 

 
           
             14  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            14 

Thr Leu Pro Ser Pro Leu Ala Leu Leu Thr Val His 
1               5                   10 

 
           
             15  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            15 

Thr Asn Arg His Asn Pro His His Leu His His Val 
1               5                   10 

 
           
             16  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            16 

Trp Pro His Ala Trp Lys Val Trp Trp Pro Ala Ser 
1               5                   10 

 
           
             17  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            17 

Asn Trp Trp Trp Pro Pro Tyr Ile Arg His Gln Pro 
1               5                   10 

 
           
             18  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            18 

Trp His Trp Ser Trp Thr Pro Trp Pro Ser His His 
1               5                   10 

 
           
             19  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            19 

Trp Pro Trp Ala Trp His Pro Ser Arg Asp Val Tyr 
1               5                   10 

 
           
             20  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            20 

Trp His Gly Tyr Trp Tyr Ser Asn Leu Asn Thr Thr 
1               5                   10 

 
           
             21  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            21 

Trp Trp Thr Pro Trp Met Ser His Ala Tyr Pro Val 
1               5                   10 

 
           
             22  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            22 

Trp Pro Asn Pro Tyr Trp Gly Trp Phe Ala Ala Val 
1               5                   10 

 
           
             23  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            23 

Thr Ser Trp His Thr Trp Trp Trp Arg Gln Pro Pro 
1               5                   10 

 
           
             24  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            24 

Asn Ala Trp His Lys Tyr Trp Trp Pro Ile Thr Lys 
1               5                   10 

 
           
             25  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            25 

His Pro Asn Asn Asp Trp Ser Lys Ala Pro Gln Phe 
1               5                   10 

 
           
             26  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            26 

Trp Trp Thr Pro Gln Pro Trp Trp Ser Phe Pro Ile 
1               5                   10 

 
           
             27  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            27 

Trp Pro His Thr Ser Trp Trp Gln Thr Pro Leu Thr 
1               5                   10 

 
           
             28  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            28 

Trp His Val Asn Trp Asp Pro Met Ala Trp Tyr Arg 
1               5                   10 

 
           
             29  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            29 

Ser Trp Pro Trp Trp Thr Ala Tyr Arg Val His Ser 
1               5                   10 

 
           
             30  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            30 

Trp His Ser Asn Trp Tyr Gln Ser Ile Pro Gln Val 
1               5                   10 

 
           
             31  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            31 

Gly Tyr Trp Pro Trp Lys Phe Glu His Ala Thr Val 
1               5                   10 

 
           
             32  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            32 

Ala Trp Trp Pro Thr Thr Phe Pro Pro Tyr Tyr Tyr 
1               5                   10 

 
           
             33  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            33 

Asn Pro Trp Trp Ser His Tyr Tyr Pro Arg Ser Val 
1               5                   10 

 
           
             34  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            34 

Trp Pro His Asn Tyr Pro Leu Asn His Ser Asn Pro 
1               5                   10 

 
           
             35  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            35 

Thr Trp Ala His Pro Leu Glu Ser Asp Tyr Leu Arg 
1               5                   10 

 
           
             36  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            36 

His Thr Tyr Tyr His Asp Gly Trp Arg Leu Ala Pro 
1               5                   10 

 
           
             37  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            37 

Thr Phe Val Gln Thr Pro Leu Ser His Leu Ile Ala 
1               5                   10 

 
           
             38  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            38 

Arg Val Pro Pro Ser Lys Leu Thr Arg Pro Pro Phe 
1               5                   10 

 
           
             39  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            39 

His Ser Ile Tyr Ser Val Thr Pro Ser Thr Ala Ser 
1               5                   10 

 
           
             40  
             12  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            40 

Leu Asn Thr Gln Asn His Ala Pro Leu Pro Ser Ile 
1               5                   10 

 
           
             41  
             32  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            41 

Lys Tyr Asp Ser Arg His Leu His Thr His Ser His Gly Gly Gly Ser 
1               5                   10                  15 

Gly Gly Gly Ser Pro Asn Arg Leu Gly Arg Arg Pro Val Arg Trp Glu 
            20                  25                  30 

 
           
             42  
             32  
             PRT  
             Artificial  
             
               binding peptide  
             
           
            42 

Trp Pro His Ala Trp Lys Val Trp Trp Pro Ala Ser Gly Gly Gly Ser 
1               5                   10                  15 

Gly Gly Gly Ser Asn Trp Trp Trp Pro Pro Tyr Ile Arg His Gln Pro 
            20                  25                  30 

 
           
             43  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            43 

gatccaaata tgatagccgt catctgcata cccatagcca tgagct                    46 

 
           
             44  
             38  
             DNA  
             Artificial  
             
               complementary to 43  
             
           
            44 

catggctatg ggtatgcaga tgacggctat catatttg                             38 

 
           
             45  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            45 

gatccccgaa ccgtctgggc cgtcgtccgg tgcgttggga agagct                    46 

 
           
             46  
             38  
             DNA  
             Artificial  
             
               complementary to 45  
             
           
            46 

cttcccaacg caccggacga cggcccagac ggttcggg                             38 

 
           
             47  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            47 

gatccaaatg ctgctattat gatcatagcc atgcgctgag cgagct                    46 

 
           
             48  
             38  
             DNA  
             Artificial  
             
               complementary to 47  
             
           
            48 

cgctcagcgc atggctatga tcataatagc agcatttg                             38 

 
           
             49  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            49 

gatccgaata tctgagcgcg attgtggcgg gcccgtggcc ggagct                    46 

 
           
             50  
             38  
             DNA  
             Artificial  
             
               complementary to 49  
             
           
            50 

ccggccacgg gcccgccaca atcgcgctca gatattcg                             38 

 
           
             51  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            51 

gatccaaact gtggattctg gaaccgaccg tgaccccgac cgagct                    46 

 
           
             52  
             38  
             DNA  
             Artificial  
             
               complementary to 51  
             
           
            52 

cggtcggggt cacggtcggt tccagaatcc acagtttg                             38 

 
           
             53  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            53 

gatcccagag caacctgaaa gtgattccga gctggtggtt tgagct                    46 

 
           
             54  
             38  
             DNA  
             Artificial  
             
               complementary to 53  
             
           
            54 

caaaccacca gctcggaatc actttcaggt tgctctgg                             38 

 
           
             55  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            55 

gatcctggat tccgccgcag tggagccgtc tgattgaacc ggagct                    46 

 
           
             56  
             38  
             DNA  
             Artificial  
             
               complementary to 55  
             
           
            56 

ccggttcaat cagacggctc cactgcggcg gaatccag                             38 

 
           
             57  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            57 

gatccgatca tccgcaggcg aaaccgaact ggtatggcgt ggagct                    46 

 
           
             58  
             38  
             DNA  
             Artificial  
             
               complementary to 57  
             
           
            58 

ccacgccata ccagttcggt ttcgcctgcg gatgatcg                             38 

 
           
             59  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            59 

gatccggcct gccgccgtat agcccgcatc gtctggcgca ggagct                    46 

 
           
             60  
             38  
             DNA  
             Artificial  
             
               complementary to 59  
             
           
            60 

cctgcgccag acgatgcggg ctatacggcg gcaggccg                             38 

 
           
             61  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            61 

gatccaaact gaccacccag tatatggcgc gtagcagcag cgagct                    46 

 
           
             62  
             38  
             DNA  
             Artificial  
             
               complementary to 61  
             
           
            62 

cgctgctgct acgcgccata tactgggtgg tcagtttg                             38 

 
           
             63  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            63 

gatccaaagt gtggatgctg ccgccgctgc cgcaggcgac cgagct                    46 

 
           
             64  
             38  
             DNA  
             Artificial  
             
               complementary to 63  
             
           
            64 

cggtcgcctg cggcagcggc ggcagcatcc acactttg                             38 

 
           
             65  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            65 

gatccaacgt gaccagcacc gcgtttattg ataccccgtg ggagct                    46 

 
           
             66  
             38  
             DNA  
             Artificial  
             
               complementary to 65  
             
           
            66 

cccacggggt atcaataaac gcggtgctgg tcacgttg                             38 

 
           
             67  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            67 

gatcccgtct gaacctggat attattgcgg tgaccagcgt ggagct                    46 

 
           
             68  
             38  
             DNA  
             Artificial  
             
               complementary to 67  
             
           
            68 

ccacgctggt caccgcaata atatccaggt tcagacgg                             38 

 
           
             69  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            69 

gatccaccct gccgagcccg ctggcgctgc tgaccgtgca tgagct                    46 

 
           
             70  
             38  
             DNA  
             Artificial  
             
               complementary to 69  
             
           
            70 

catgcacggt cagcagcgcc agcgggctcg gcagggtg                             38 

 
           
             71  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            71 

gatccaccaa ccgtcataac ccgcatcatc tgcatcatgt ggagct                    46 

 
           
             72  
             38  
             DNA  
             Artificial  
             
               complementary to 71  
             
           
            72 

ccacatgatg cagatgatgc gggttatgac ggttggtg                             38 

 
           
             73  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            73 

gatcctggcc gcatgcgtgg aaagtgtggt ggccggcgag cgagct                    46 

 
           
             74  
             38  
             DNA  
             Artificial  
             
               complementary to 73  
             
           
            74 

cgctcgccgg ccaccacact ttccacgcat gcggccag                             38 

 
           
             75  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            75 

gatccaactg gtggtggccg ccgtatattc gtcatcagcc ggagct                    46 

 
           
             76  
             38  
             DNA  
             Artificial  
             
               complementary to 75  
             
           
            76 

ccggctgatg acgaatatac ggcggccacc accagttg                             38 

 
           
             77  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            77 

gatcctggca ttggagctgg accccgtggc cgagccatca tgagct                    46 

 
           
             78  
             38  
             DNA  
             Artificial  
             
               complementary to 77  
             
           
            78 

catgatggct cggccacggg gtccagctcc aatgccag                             38 

 
           
             79  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            79 

gatcctggcc gtgggcgtgg catccgagcc gtgatgtgta tgagct                    46 

 
           
             80  
             38  
             DNA  
             Artificial  
             
               complementary to 79  
             
           
            80 

catacacatc acggctcgga tgccacgccc acggccag                             38 

 
           
             81  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            81 

gatcctggca tggctattgg tatagcaacc tgaacaccac cgagct                    46 

 
           
             82  
             38  
             DNA  
             Artificial  
             
               complementary to 81  
             
           
            82 

cggtggtgtt caggttgcta taccaatagc catgccag                             38 

 
           
             83  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            83 

gatcctggtg gaccccgtgg atgagccatg cgtatccggt ggagct                    46 

 
           
             84  
             38  
             DNA  
             Artificial  
             
               complementary to 83  
             
           
            84 

ccaccggata cgcatggctc atccacgggg tccaccag                             38 

 
           
             85  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            85 

gatcctggcc gaacccgtat tggggctggt ttgcggcggt ggagct                    46 

 
           
             86  
             38  
             DNA  
             Artificial  
             
               complementary to 85  
             
           
            86 

ccaccgccgc aaaccagccc caatacgggt tcggccag                             38 

 
           
             87  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            87 

gatccaccag ctggcatacc tggtggtggc gtcagccgcc ggagct                    46 

 
           
             88  
             38  
             DNA  
             Artificial  
             
               87  
             
           
            88 

ccggcggctg acgccaccac caggtatgcc agctggtg                             38 

 
           
             89  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            89 

gatccaacgc gtggcataaa tattggtggc cgattaccaa agagct                    46 

 
           
             90  
             38  
             DNA  
             Artificial  
             
               complementary to 89  
             
           
            90 

ctttggtaat cggccaccaa tatttatgcc acgcgttg                             38 

 
           
             91  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            91 

gatcccatcc gaacaacgat tggagcaaag cgccgcagtt tgagct                    46 

 
           
             92  
             38  
             DNA  
             Artificial  
             
               complementary to 91  
             
           
            92 

caaactgcgg cgctttgctc caatcgttgt tcggatgg                             38 

 
           
             93  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            93 

gatcctggtg gaccccgcag ccgtggtgga gctttccgat tgagct                    46 

 
           
             94  
             38  
             DNA  
             Artificial  
             
               complementary to 93  
             
           
            94 

caatcggaaa gctccaccac ggctgcgggg tccaccag                             38 

 
           
             95  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            95 

gatcctggcc gcataccagc tggtggcaga ccccgctgac cgagct                    46 

 
           
             96  
             38  
             DNA  
             Artificial  
             
               95  
             
           
            96 

cggtcagcgg ggtctgccac cagctggtat gcggccag                             38 

 
           
             97  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            97 

gatcctggca tgtgaactgg gatccgatgg cgtggtatcg tgagct                    46 

 
           
             98  
             38  
             DNA  
             Artificial  
             
               complementary to 97  
             
           
            98 

cacgatacca cgccatcgga tcccagttca catgccag                             38 

 
           
             99  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            99 

gatccagctg gccgtggtgg accgcgtatc gtgtgcatag cgagct                    46 

 
           
             100  
             38  
             DNA  
             Artificial  
             
               complementary to 99  
             
           
            100 

cgctatgcac acgatacgcg gtccaccacg gccagctg                             38 

 
           
             101  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            101 

gatcctggca tagcaactgg tatcagagca ttccgcaggt ggagct                    46 

 
           
             102  
             38  
             DNA  
             Artificial  
             
               complementary to 101  
             
           
            102 

ccacctgcgg aatgctctga taccagttgc tatgccag                             38 

 
           
             103  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            103 

gatccggcta ttggccgtgg aaatttgaac atgcgaccgt ggagct                    46 

 
           
             104  
             38  
             DNA  
             Artificial  
             
               complementary to 103  
             
           
            104 

ccacggtcgc atgttcaaat ttccacggcc aatagccg                             38 

 
           
             105  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            105 

gatccgcgtg gtggccgacc acctttccgc cgtattatta tgagct                    46 

 
           
             106  
             38  
             DNA  
             Artificial  
             
               complementary to 105  
             
           
            106 

cataataata cggcggaaag gtggtcggcc accacgcg                             38 

 
           
             107  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            107 

gatccaaccc gtggtggagc cattattatc cgcgtagcgt ggagct                    46 

 
           
             108  
             38  
             DNA  
             Artificial  
             
               complementary to 107  
             
           
            108 

ccacgctacg cggataataa tggctccacc acgggttg                             38 

 
           
             109  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            109 

gatcctggcc gcataactat ccgctgaacc atagcaaccc ggagct                    46 

 
           
             110  
             38  
             DNA  
             Artificial  
             
               complementary to 109  
             
           
            110 

ccgggttgct atggttcagc ggatagttat gcggccag                             38 

 
           
             111  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            111 

gatccacctg ggcgcatccg ctggaaagcg attatctgcg tgagct                    46 

 
           
             112  
             38  
             DNA  
             Artificial  
             
               complementary to 111  
             
           
            112 

cacgcagata atcgctttcc agcggatgcg cccaggtg                             38 

 
           
             113  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            113 

gatcccatac ctattatcat gatggctggc gtctggcgcc ggagct                    46 

 
           
             114  
             38  
             DNA  
             Artificial  
             
               complementary to 113  
             
           
            114 

ccggcgccag acgccagcca tcatgataat aggtatgg                             38 

 
           
             115  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            115 

gatccacctt tgtgcagacc ccgctgagcc atctgattgc ggagct                    46 

 
           
             116  
             38  
             DNA  
             Artificial  
             
               complementary to 115  
             
           
            116 

ccgcaatcag atggctcagc ggggtctgca caaaggtg                             38 

 
           
             117  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            117 

gatcccgtgt gccgccgagc aaactgaccc gtccgccgtt tgagct                    46 

 
           
             118  
             38  
             DNA  
             Artificial  
             
               complementary to 117  
             
           
            118 

caaacggcgg acgggtcagt ttgctcggcg gcacacgg                             38 

 
           
             119  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            119 

gatcccatag catttatagc gtgaccccga gcaccgcgag cgagct                    46 

 
           
             120  
             38  
             DNA  
             Artificial  
             
               complementary to 119  
             
           
            120 

cgctcgcggt gctcggggtc acgctataaa tgctatgg                             38 

 
           
             121  
             46  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            121 

gatccctgaa cacccagaac catgcgccgc tgccgagcat tgagct                    46 

 
           
             122  
             38  
             DNA  
             Artificial  
             
               complementary to 121  
             
           
            122 

caatgctcgg cagcggcgca tggttctggg tgttcagg                             38 

 
           
             123  
             106  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            123 

gatccaaata tgatagccgt catctgcata cccatagcca tggcggcggc agcggcggcg     60 

gcagcccgaa ccgtctgggc cgtcgtccgg tgcgttggga agagct                   106 

 
           
             124  
             98  
             DNA  
             Artificial  
             
               complementary to 123  
             
           
            124 

cttcccaacg caccggacga cggcccagac ggttcgggct gccgccgccg ctgccgccgc     60 

catggctatg ggtatgcaga tgacggctat catatttg                             98 

 
           
             125  
             106  
             DNA  
             Artificial  
             
               binding peptide  
             
           
            125 

gatcctggcc gcatgcgtgg aaagtgtggt ggccggcgag cggcggcggc agcggcggcg     60 

gcagcaactg gtggtggccg ccgtatattc gtcatcagcc ggagct                   106 

 
           
             126  
             98  
             DNA  
             Artificial  
             
               complementary to 125  
             
           
            126 

ccggctgatg acgaatatac ggcggccacc accagttgct gccgccgccg ctgccgccgc     60 

cgctcgccgg ccaccacact ttccacgcat gcggccag                             98 

 
           
             127  
             30  
             DNA  
             Artificial  
             
               5′ primer for NS4  
             
           
            127 

ttcacaggat ccactgagct cgatgcccac                                      30 

 
           
             128  
             30  
             DNA  
             artificial  
             
               3′primer for NS4  
             
           
            128 

gatctgggct cgagccgact agtagtcgct                                      30 

 
           
             129  
             7  
             PRT  
             artificial  
             
               spacer  
             
           
            129 

Gly Gly Gly Ser Gly Gly Ser 
1               5